더바이오 10월 26일 주요뉴스

[https://www.thebionews.net/edit/webzine.html?idxno=670](https://www.thebionews.net/edit/webzine.html?idxno=670)

● ‘키트루다 SC’, 정맥주사 얼마나 대체할까…美 확산 속 국내 전환 변수는
[https://www.thebionews.net/news/articleView.html?idxno=29410](https://www.thebionews.net/news/articleView.html?idxno=29410)

● [ESMO] 굽타 노바브릿지 CEO “지바스토믹, 기술이전·자체 임상3상 병행”
[https://www.thebionews.net/news/articleView.html?idxno=29417](https://www.thebionews.net/news/articleView.html?idxno=29417)

● [ESMO] 에임드바이오 “FGFR3 ADC 항종양 활성 첫 입증…새 시장 열린다”
[https://www.thebionews.net/news/articleView.html?idxno=29415](https://www.thebionews.net/news/articleView.html?idxno=29415)

● 삼성바이오, ‘매출 4조·현금 2조’ 돌파…차입금 줄이고 6공장 실탄까지 확보
[https://www.thebionews.net/news/articleView.html?idxno=29411](https://www.thebionews.net/news/articleView.html?idxno=29411)

● [단독] 보령, ‘네시나·액토스’ 판권 확보…오리지널 당뇨약 공백 메우나
[https://www.thebionews.net/news/articleView.html?idxno=29470](https://www.thebionews.net/news/articleView.html?idxno=29470)

● 로슈, 자임웍스 DLL3 표적 삼중특이항체 ‘ZW209’ 1.1조원 규모 도입
[https://www.thebionews.net/news/articleView.html?idxno=29458](https://www.thebionews.net/news/articleView.html?idxno=29458)

● [ESMO] 中 아케소, ‘이보네시맙’ 담도암 3상서 ‘임핀지’ 대비 사망 위험 25%↓
[https://www.thebionews.net/news/articleView.html?idxno=29421](https://www.thebionews.net/news/articleView.html?idxno=29421)

● [ESMO] BMS·바이오엔테크 ‘푸미타미그’, 폐암 2상 반응률 36.7%·DCR 90%
[https://www.thebionews.net/news/articleView.html?idxno=29456](https://www.thebionews.net/news/articleView.html?idxno=29456)

● [ESMO] J&J, ‘JNJ-6143’ 전립선암 1상 종양 반응률 75%…77%, PSA 절반↓
[https://www.thebionews.net/news/articleView.html?idxno=29454](https://www.thebionews.net/news/articleView.html?idxno=29454)

● [ESMO] J&J, ‘리브리반트SC’ 두경부암 1b·2상 77% 반응…완전관해도 14%
[https://www.thebionews.net/news/articleView.html?idxno=29450](https://www.thebionews.net/news/articleView.html?idxno=29450)

● ‘마운자로’ 적응증 확대…‘심혈관 사건 위험 감소·10세 이상 소아 당뇨병’ 허가
[https://www.thebionews.net/news/articleView.html?idxno=29439](https://www.thebionews.net/news/articleView.html?idxno=29439)

● ‘BIX 2026’ 역대 최대 규모 개최…300개 기업·600개 부스 참가
[https://www.thebionews.net/news/articleView.html?idxno=29434](https://www.thebionews.net/news/articleView.html?idxno=29434)

● [ESMO] 프레지덴셜 12건 중 中 신약 5건…“韓 뉴모달리티 지속 지원해야”
[https://www.thebionews.net/news/articleView.html?idxno=29412](https://www.thebionews.net/news/articleView.html?idxno=29412)

● [ESMO] 로슈, ‘디바라십’ KRAS G12C 변이 폐암 임상3상 사망 위험 44%↓
[https://www.thebionews.net/news/articleView.html?idxno=29418](https://www.thebionews.net/news/articleView.html?idxno=29418)

● [ESMO] AZ, ‘소네시타투그 베도틴’ 위암 3상 사망위험 53%↓…생존기간 2배
[https://www.thebionews.net/news/articleView.html?idxno=29420](https://www.thebionews.net/news/articleView.html?idxno=29420)

● [ESMO] ‘타그리소·오파티스’, 폐암 3상 사망 위험 32%↓…생존 4.9개월 연장
[https://www.thebionews.net/news/articleView.html?idxno=29419](https://www.thebionews.net/news/articleView.html?idxno=29419)

● [ESMO] 리가켐바이오, CLDN18.2 ADC ‘LCB02A’ 전임상·임상 포스터 공개
[https://www.thebionews.net/news/articleView.html?idxno=29451](https://www.thebionews.net/news/articleView.html?idxno=29451)

● 셀트리온, 1000억원 규모 자사주 추가 매입…올해 누적 5000억원
[https://www.thebionews.net/news/articleView.html?idxno=29455](https://www.thebionews.net/news/articleView.html?idxno=29455)

● 한미약품, LDL-C부터 혈압까지…심혈관계 통합 관리 전략 제시
[https://www.thebionews.net/news/articleView.html?idxno=29452](https://www.thebionews.net/news/articleView.html?idxno=29452)

● [카드뉴스] 더바이오 주간 ‘톱10’ 뉴스(10월 4주차)
[https://www.thebionews.net/news/articleView.html?idxno=29375](https://www.thebionews.net/news/articleView.html?idxno=29375)

●Alteogen earns ESG rating firm EcoVadis’ ‘Gold Medal,’ joining global top 4%
[https://www.thebionews.net/news/articleView.html?idxno=29467](https://www.thebionews.net/news/articleView.html?idxno=29467)

●Orum Therapeutics CEO SJ Lee: “Autonomous leadership and horizontal research culture underpin success of Daejeon’s bio industry”
[https://www.thebionews.net/news/articleView.html?idxno=29462](https://www.thebionews.net/news/articleView.html?idxno=29462)

●L&C BIO presents skin human tissue ECM reconstruction case study at Korean Breast Cancer Society
[https://www.thebionews.net/news/articleView.html?idxno=29461](https://www.thebionews.net/news/articleView.html?idxno=29461)

●Turkish Health Minister tours Curocell’s clinical manufacturing facility for CAR-T therapy ‘RIMQARTO’
[https://www.thebionews.net/news/articleView.html?idxno=29460](https://www.thebionews.net/news/articleView.html?idxno=29460)

●Rznomics secures European orphan drug designation for anticancer gene therapy candidate ‘RZ-001’
[https://www.thebionews.net/news/articleView.html?idxno=29459](https://www.thebionews.net/news/articleView.html?idxno=29459)

●‘BIX 2026’ Pre-Registration Closes Today Ahead of a Record-Breaking Edition
[https://www.thebionews.net/news/articleView.html?idxno=29445](https://www.thebionews.net/news/articleView.html?idxno=29445)

*제약바이오 10월 26일 아침 유튜브 라디오 뉴스(매일 아침 업로드)
[https://www.youtube.com/watch?v=zdoV8TxRgoA](https://www.youtube.com/watch?v=zdoV8TxRgoA)